128 related articles for article (PubMed ID: 35512029)
21. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
22. Kr-POK (ZBTB7c) regulates cancer cell proliferation through glutamine metabolism.
Hur MW; Yoon JH; Kim MY; Ko H; Jeon BN
Biochim Biophys Acta Gene Regul Mech; 2017 Aug; 1860(8):829-838. PubMed ID: 28571744
[TBL] [Abstract][Full Text] [Related]
23. Loss of heterozygosity for Kras
Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
[TBL] [Abstract][Full Text] [Related]
24. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Masamha CP; LaFontaine P
J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
[TBL] [Abstract][Full Text] [Related]
25. Detachable MOF-Based Core/Shell Nanoreactor for Cancer Dual-Starvation Therapy With Reversing Glucose and Glutamine Metabolisms.
Du H; Meng S; Geng M; Zhao P; Gong L; Zheng X; Li X; Yuan Z; Yang H; Zhao Y; Dai L
Small; 2023 Oct; 19(42):e2303253. PubMed ID: 37330663
[TBL] [Abstract][Full Text] [Related]
26. Growth and metabolism of marine fish Chinook salmon embryo cells: response to lack of glucose and glutamine.
Chen J; Sun X; Zhang Y
Biotechnol Lett; 2005 Mar; 27(6):395-401. PubMed ID: 15834804
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.
Gaglio D; Metallo CM; Gameiro PA; Hiller K; Danna LS; Balestrieri C; Alberghina L; Stephanopoulos G; Chiaradonna F
Mol Syst Biol; 2011 Aug; 7():523. PubMed ID: 21847114
[TBL] [Abstract][Full Text] [Related]
28. Silencing of glutaminase 1 resensitizes Taxol-resistant breast cancer cells to Taxol.
Fu A; Yu Z; Song Y; Zhang E
Mol Med Rep; 2015 Jun; 11(6):4727-33. PubMed ID: 25625774
[TBL] [Abstract][Full Text] [Related]
29. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
[TBL] [Abstract][Full Text] [Related]
30. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment.
Tirella A; Kloc-Muniak K; Good L; Ridden J; Ashford M; Puri S; Tirelli N
Int J Pharm; 2019 Apr; 561():114-123. PubMed ID: 30822503
[TBL] [Abstract][Full Text] [Related]
31. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.
Son J; Lyssiotis CA; Ying H; Wang X; Hua S; Ligorio M; Perera RM; Ferrone CR; Mullarky E; Shyh-Chang N; Kang Y; Fleming JB; Bardeesy N; Asara JM; Haigis MC; DePinho RA; Cantley LC; Kimmelman AC
Nature; 2013 Apr; 496(7443):101-5. PubMed ID: 23535601
[TBL] [Abstract][Full Text] [Related]
32. miR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells.
Li J; Li X; Wu L; Pei M; Li H; Jiang Y
Cell Biol Int; 2019 Aug; 43(8):921-930. PubMed ID: 31115975
[TBL] [Abstract][Full Text] [Related]
33. Activation of p53 by costunolide blocks glutaminolysis and inhibits proliferation in human colorectal cancer cells.
Hu M; Liu L; Yao W
Gene; 2018 Dec; 678():261-269. PubMed ID: 30103008
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
[TBL] [Abstract][Full Text] [Related]
35. Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth.
van den Heuvel AP; Jing J; Wooster RF; Bachman KE
Cancer Biol Ther; 2012 Oct; 13(12):1185-94. PubMed ID: 22892846
[TBL] [Abstract][Full Text] [Related]
36. Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis.
Lee EJ; Duggirala KB; Lee Y; Yun MR; Jang J; Cyriac R; Jung ME; Choi G; Chae CH; Cho BC; Lee K
Bioorg Med Chem Lett; 2022 Nov; 75():128956. PubMed ID: 36038117
[TBL] [Abstract][Full Text] [Related]
37. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
[TBL] [Abstract][Full Text] [Related]
38. Glutaminase sustains cell survival via the regulation of glycolysis and glutaminolysis in colorectal cancer.
Song Z; Wei B; Lu C; Li P; Chen L
Oncol Lett; 2017 Sep; 14(3):3117-3123. PubMed ID: 28928849
[TBL] [Abstract][Full Text] [Related]
39. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
40. U1 Adaptors Suppress the
Tsang AT; Dudgeon C; Yi L; Yu X; Goraczniak R; Donohue K; Kogan S; Brenneman MA; Ho ES; Gunderson SI; Carpizo DR
Mol Cancer Ther; 2017 Aug; 16(8):1445-1455. PubMed ID: 28377488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
